AstraZeneca PLC Valuation
| AZN Stock | USD 72.50 2.02 2.87% |
At this time, the firm appears to be undervalued. AstraZeneca PLC ADR shows a prevailing Real Value of $77.36 per share. The current price of the firm is $72.5. Our model approximates the value of AstraZeneca PLC ADR from analyzing the firm fundamentals such as Profit Margin of 0.14 %, current valuation of 238.68 B, and Return On Equity of 0.2 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting AstraZeneca PLC's valuation include:
Price Book 5.1917 | Enterprise Value | Enterprise Value Ebitda 14.9126 | Price Sales 3.8983 | Forward PE 15.2905 |
Undervalued
Today
Please note that AstraZeneca PLC's price fluctuation is very steady at this time. Calculation of the real value of AstraZeneca PLC ADR is based on 3 months time horizon. Increasing AstraZeneca PLC's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since AstraZeneca PLC is currently traded on the exchange, buyers and sellers on that exchange determine the market value of AstraZeneca Stock. However, AstraZeneca PLC's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 72.5 | Real 77.36 | Target 84.18 | Hype 70.44 | Naive 71.43 |
The intrinsic value of AstraZeneca PLC's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence AstraZeneca PLC's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of AstraZeneca PLC ADR helps investors to forecast how AstraZeneca stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of AstraZeneca PLC more accurately as focusing exclusively on AstraZeneca PLC's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use AstraZeneca PLC's intrinsic value based on its ongoing forecasts of AstraZeneca PLC's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against AstraZeneca PLC's closest peers.
AstraZeneca PLC Cash |
|
AstraZeneca Valuation Trend
Knowing AstraZeneca PLC's actual value is paramount for traders when making sound investment determinations. Using both AstraZeneca PLC's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
AstraZeneca Revenue by Product
AstraZeneca PLC Total Value Analysis
AstraZeneca PLC ADR is presently forecasted to have company total value of 238.68 B with market capitalization of 214.34 B, debt of 30.11 B, and cash on hands of 4.52 B. Please note that company total value may be misleading and is a subject to accounting gimmicks. We encourage investors to carefully check all of the AstraZeneca PLC fundamentals before making security assessment based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
238.68 B | 214.34 B | 30.11 B | 4.52 B |
AstraZeneca PLC Investor Information
About 17.0% of the company shares are held by institutions such as insurance companies. The company has Price/Earnings To Growth (PEG) ratio of 0.92. AstraZeneca PLC ADR last dividend was issued on the 21st of February 2025. The entity had 2:1 split on the 27th of July 2015. Based on the measurements of operating efficiency obtained from AstraZeneca PLC's historical financial statements, AstraZeneca PLC ADR is doing better financially today then in previous quarter. It has a moderate probability of reporting better financial numbers in August.| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Profit Margin | 0.22 | 0.185 |
|
| |||||
| Total Cash From Operating Activities | 12.5 B | 11.9 B |
|
| |||||
| Operating Income | 5.2 B | 10 B |
|
|
AstraZeneca PLC Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. AstraZeneca PLC has an asset utilization ratio of 51.98 percent. This suggests that the Company is making $0.52 for each dollar of assets. An increasing asset utilization means that AstraZeneca PLC ADR is more efficient with each dollar of assets it utilizes for everyday operations.AstraZeneca PLC Ownership Allocation
AstraZeneca PLC holds a total of 3.1 Billion outstanding shares. Almost 82.93 percent of AstraZeneca PLC outstanding shares are held by general public with 17.07 % by other corporate entities. Please note that on May 13, 2025, Representative Bruce Westerman of US Congress acquired under $15k worth of AstraZeneca PLC ADR's common stock.AstraZeneca PLC Profitability Analysis
The company reported the last year's revenue of 54.07 B. Total Income to common stockholders was 8.69 B with profit before taxes, overhead, and interest of 45.33 B.AstraZeneca PLC Past Distributions to stockholders
About AstraZeneca PLC Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of AstraZeneca PLC ADR. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of AstraZeneca PLC ADR based exclusively on its fundamental and basic technical indicators. By analyzing AstraZeneca PLC's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of AstraZeneca PLC's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of AstraZeneca PLC. We calculate exposure to AstraZeneca PLC's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of AstraZeneca PLC's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 43.9 B | 46.1 B | |
| Pretax Profit Margin | 0.16 | 0.20 | |
| Operating Profit Margin | 0.18 | 0.22 | |
| Net Profit Margin | 0.13 | 0.10 | |
| Gross Profit Margin | 0.81 | 0.63 |
A single share of AstraZeneca PLC represents a small ownership stake in the entity. As a stockholder of AstraZeneca, your percentage of company ownership is determined by dividing the number of shares you own by the total number of shares outstanding and then multiplying that amount by 100. Owning stock in a company generally confers both corporate voting rights and income from any dividends paid to the stock owner.
AstraZeneca PLC Dividends Analysis For Valuation
As of the 23rd of July 2025, Dividend Paid And Capex Coverage Ratio is likely to grow to 1.31, while Dividends Paid is likely to drop about 3.3 B. . As of the 23rd of July 2025, Price Earnings To Growth Ratio is likely to grow to 1.58, while Retained Earnings are likely to drop about 3 B.
| Last Reported | Projected for Next Year | ||
| Dividends Paid | 4.6 B | 3.3 B | |
| Dividend Yield | 0.02 | 0.02 | |
| Dividend Payout Ratio | 0.66 | 0.63 | |
| Dividend Paid And Capex Coverage Ratio | 1.29 | 1.31 |
There are various types of dividends AstraZeneca PLC can pay to its shareholders, and the actual value of the dividend is determined on a per-share basis. It is to be paid equally to all of AstraZeneca shareholders on a specific date, known as the payable date. The cash dividend is the most common type of dividend payment - it is the payment of actual cash from AstraZeneca PLC ADR directly to its shareholders. There are other types of dividends that companies can issue, such as stock dividends or asset dividends. When AstraZeneca pays a dividend, it has no impact on its enterprise value. It does, however, lowers the Equity Value of AstraZeneca PLC by the value of the dividends paid out.
AstraZeneca PLC Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 6.3 B | |
| Quarterly Earnings Growth Y O Y | 0.336 | |
| Forward Price Earnings | 15.2905 |
AstraZeneca PLC Current Valuation Indicators
AstraZeneca PLC's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final AstraZeneca PLC's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as AstraZeneca PLC, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use AstraZeneca PLC's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes AstraZeneca PLC's worth.When determining whether AstraZeneca PLC ADR offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of AstraZeneca PLC's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Astrazeneca Plc Adr Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Astrazeneca Plc Adr Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in AstraZeneca PLC ADR. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of AstraZeneca PLC. If investors know AstraZeneca will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about AstraZeneca PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.336 | Dividend Share 3.1 | Earnings Share 2.49 | Revenue Per Share | Quarterly Revenue Growth 0.072 |
The market value of AstraZeneca PLC ADR is measured differently than its book value, which is the value of AstraZeneca that is recorded on the company's balance sheet. Investors also form their own opinion of AstraZeneca PLC's value that differs from its market value or its book value, called intrinsic value, which is AstraZeneca PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because AstraZeneca PLC's market value can be influenced by many factors that don't directly affect AstraZeneca PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between AstraZeneca PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if AstraZeneca PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, AstraZeneca PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.